ANDOVER,
Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients
with end-stage lung, heart and liver failure, today announced that
it will release financial results for the third quarter 2024 after
market close on Monday, October 28,
2024. The TransMedics management team will host a
corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m.
PT.
Investors interested in listening to the conference call may do
so by dialing (844) 481-2832 for domestic callers or (412) 317-1852
for international callers and ask to be joined into the TransMedics
call. A live and archived webcast of the event will be available on
the "Investors" section of the TransMedics website at
https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the
world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian
Johnston
332-895-3222
Investors@transmedics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-third-quarter-2024-financial-results-on-october-28-2024-302276974.html
SOURCE TransMedics Group, Inc.